Vascular Interventional Advances (VIVA)

The VIVA Foundation is a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education, research, advocacy, and collaboration. It hosts the VIVA (Vascular InterVentional Advances) and The VEINS (Venous Endovascular INterventional Strategies) annual conferences. The VIVA Foundation also presents the Vascular Leaders Forum and collaborates with other industry-leading groups to move the field forward.

Mechanical thrombectomy beats anticoagulation alone in STORM-PE
Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.
Shockwave Medical’s IVL catheter for peripheral lesions linked to positive 1-year data
The new findings, presented during a late-breaking presentation, focused on 110 PAD patients treated with Shockwave Medical's Javelin Peripheral IVL Catheter.
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.
Drug-coated balloons an effective tool in the battle against femoropopliteal disease
Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.

Video Robert Lookstein on mechanical thrombectomy beating anticoagulation alone in pulmonary embolism in the late-breaking STORM-PE trial at TCT 2025.

Mechanical thrombectomy beats anticoagulation alone in STORM-PE

Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.

Shockwave Medical Javelin Peripheral IVL Catheter

Shockwave Medical’s IVL catheter for peripheral lesions linked to positive 1-year data

The new findings, presented during a late-breaking presentation, focused on 110 PAD patients treated with Shockwave Medical's Javelin Peripheral IVL Catheter.

The Abbott Esprit BTK everolimus-eluting biosorbable scaffold system for below the knee peripheral artery disease on display at TCT 2024. Photo by Dave FornellTCTn 2024 DF

Bioresorbable BTK stent superior to ballon angioplasty at 2 years

Late-breaking data from the LIFE-BTK clinical trial showed that the Esprit BTK bioresorbable scaffold system offered better two-year outcomes than balloon angioplasty in severe peripheral artery disease (PAD) below the knee.

Shockwave Javelin Peripheral IVL Catheter

Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients

Multiple late-breaking presentations at VIVA 2024 in Las Vegas focused on the benefits of treating peripheral artery disease with the company's intravascular lithotripsy portfolio.

Drug-coated balloons an effective tool in the battle against femoropopliteal disease

Two late-breaking clinical trials presented at the VIVA Foundation’s VIVA22 conference in Las Vegas highlighted the impact drug-coated balloons can make on patient outcomes.

Late-breaking study examines IVL’s safety and effectiveness among real-life PAD patients

The new study, based on data from nearly 1,400 PAD patients who were treated with Shockwave Medical's IVL technology, was presented at VIVA22 in Las Vegas.

Many PAD patients are missing out on vital risk assessments

The findings, based on Medicare data, were presented at VIVA21 in Las Vegas.

Arizona patients successfully receive the world’s first bioconvertible IVC filter commercially offered in US

BTG plc (LSE: BTG), the global healthcare company, today announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device – the world’s first bioconvertible IVC filter.